Epigeneres Biotech is a biotech startup based in Mumbai, India, that develops molecular medicines, nutrigenomic formulations and cancer detection tests for patients with cancer and ageing-related diseases.

This Startup Deep Dive explains what Epigeneres Biotech does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Epigeneres Biotech in Brief

• What it is: Epigeneres Biotech is an Indian Cancer diagnostics biotech company based in Mumbai.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• The company discovers, develops, manufactures and commercialises molecular medicines and nutrigenomic formulations for serious conditions including cancer and ageing-related diseases.
• In May 2021 it announced an early cancer detection blood test built on RNA biomarker technology, co-developed with Singapore-based Tzar Labs.
• It is reported to be the exclusive licensee in India of Tzar Labs' technology.
• Funding: About $12 million (Inc42); Series B of $6 million in January 2022.

Epigeneres Biotech Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Epigeneres Biotech?

Epigeneres Biotech operates in the Cancer diagnostics biotech space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Epigeneres Biotech.

• The company discovers, develops, manufactures and commercialises molecular medicines and nutrigenomic formulations for serious conditions including cancer and ageing-related diseases.
• In May 2021 it announced an early cancer detection blood test built on RNA biomarker technology, co-developed with Singapore-based Tzar Labs.
• It is reported to be the exclusive licensee in India of Tzar Labs' technology.
• Backers say the test can detect cancer at "Stage Zero", before a tumour forms.

The Origin Story of Epigeneres Biotech

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Ashish Tripathi (founder and chairman; spelled Anish in some profiles).
• Reports differ on the founding year: some profiles say 2008 and a registry-based profile dates the founder role to April 2012.
• Its work builds on the idea that very small embryonic-like stem cells undergo epigenetic changes into cancer stem cells; its test is meant to detect cancer at stage zero.
• Ashish Tripathi, founder and chairman, is also founder and CEO of Tzar Labs; a speaker profile says he previously headed technology, media and telecom at Edelweiss Investment Banking, with 20+ years in investment banking and an MBA from Melbourne Business School.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Cancer diagnostics biotech sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• May 2021: announced RNA biomarker based early cancer detection test with Tzar Labs.
• January 2022: raised a $6 million Series B led by Kotak Investment Advisors, Moez Daya (Satya Capital) and LetsVenture Angel Fund.
• No news of commercial launch or later funding was found after the 2022 round.

Epigeneres Biotech Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Series B of $6 million in January 2022 led by Kotak Investment Advisors, with Moez Daya and LetsVenture Angel Fund (reported).
• Other Series B investors: Ashish Kacholia, East River Advisors, One Decacorn, Nandita Advisors and Chockalingam Valliappa.
• Existing investors named: HCG, Torrent Pharma, Vijay Karnani, Venkat Ramaswamy and Sanjeev Khandelwal; earlier round amounts not stated.
• Board members named: V Krishnan and Shailesh Haribhakti.

How Does Epigeneres Biotech Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• The plan is to offer cancer early-detection testing as a service in India, backed by its own lab facilities.
• It also develops medicines and nutrigenomic formulations; pricing and revenue model were not found in sources read.

The Numbers: Epigeneres Biotech Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Audited revenue, profit and loss figures for Epigeneres Biotech were not available in the public sources reviewed.
• Readers can check the company’s filings with the Registrar of Companies for the latest financial statements.

Market Opportunity for Epigeneres Biotech

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• The pitch is early cancer detection through a simple blood test in India, which the company calls a world first at launch.

Technology and Product at Epigeneres Biotech

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• The early detection test uses RNA biomarker technology, which backers say can detect cancer before tumour formation.
• The company co-developed a cancer prognostic and diagnostic technology with Singapore-based Tzar Labs and is reportedly the sole licensee in India.
• Series B money was earmarked for an AI platform for India.

Team and Culture at Epigeneres Biotech

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Ashish Tripathi is founder and chairman; Inc42 lists Anish Tripathi as managing director.
• Profiles list roughly 63 to 85 employees; figures vary by source.

Epigeneres Biotech Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Epigeneres Biotech

• Sources read show no news after the 2022 funding, so current operating status is unclear.
• The "Stage Zero" detection claim is made by the company and its backers and was not independently verified.
• Founding year, founder name spelling and headcount differ across sources.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Epigeneres Biotech Growth Outlook: What to Watch

• Series B proceeds were earmarked for expanding lab facilities, scaling operations and building an AI platform for India.
• No later outlook statements were found.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Epigeneres Biotech can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Epigeneres Biotech Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Epigeneres Biotech

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Epigeneres Biotech.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Epigeneres Biotech

Studying a company in the Cancer diagnostics biotech space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Epigeneres Biotech.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Epigeneres Biotech as a Startup

• Customer clarity: Can Epigeneres Biotech name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Epigeneres Biotech is part of India’s growing Cancer diagnostics biotech ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Epigeneres Biotech FAQs: Frequently Asked Questions

What is Epigeneres Biotech?

Epigeneres Biotech is a biotech startup based in Mumbai, India, that develops molecular medicines, nutrigenomic formulations and cancer detection tests for patients with cancer and ageing-related diseases. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Epigeneres Biotech?

Epigeneres Biotech was founded by Ashish Tripathi (founder and chairman; spelled Anish in some profiles), and the company reports a founding year of 2012 (reports differ: some profiles say 2008).

How much funding has Epigeneres Biotech raised?

About $12 million (Inc42); Series B of $6 million in January 2022. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Epigeneres Biotech make money?

Epigeneres Biotech earns revenue from its Cancer diagnostics biotech products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Epigeneres Biotech?

Reported rivals include Datar Cancer Genetics, Epigenomics AG. See the competitor comparison above for how they differ.

What are the main risks for Epigeneres Biotech?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Okto — Okto: CoinDCX-built Web3 wallet and chain abstraction layer | Samarth Elder Care — Samarth raised Rs 12 crore for elder care in 2024. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.